Message from the Chairman and CEO
Net sales increased, due to the conversion of OGT to a subsidiary and higher reagent sales.
Profit attributable to owners of the parent grew, owing to higher operating profit and a decrease in the tax rate.
During the first three months of the fiscal year ending March 31, 2019, the Sysmex Group generated a year-on-year increase in net sales, due to the conversion of Oxford Gene Technology IP Limited (OGT) to a subsidiary and higher reagent sales, centered on the hematology1 and hemostasis fields. Operating profit and profit attributable to owners of the parent also grew, thanks to higher sales of reagents and a decrease in the tax rate. Net sales rose 6.9% year on year, operating profit increased 11.3%, and profit attributable to owners of the parent grew 14.6%. At the exchange rates prevailing one year earlier, net sales would have been up 4.7% and operating profit up 11.6%.
In Japan, sales rose, particularly in the hemostasis, immunochemistry and life science fields. Overseas, sales of reagents expanded, due to an increase in the installed instrument base mainly in the hematology field1, as well as to favorable performance in the life science field. As a result, the Group’s overseas sales ratio was 85.5%.
Our forecast for the fiscal year ending March 31, 2019, remains unchanged from our announcement in May 20182.
Anticipating future market growth, we established a subsidiary in Egypt and began direct sales and service in the country. In addition to our mainstay hematology field, we will begin providing products and services in the urinalysis, hemostasis and life science fields, as well as to address three major infectious diseases (HIV/AIDS, tuberculosis and malaria). At the same time, we aim to reinforce our sales and service structure, achieve further increases in customer satisfaction and expand our business.
1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.
2 These forecasts are based on information available as of the date of this message. Actual results may differ materially from these forecasts due to unforeseen factors and future events.